1. Search Result
Search Result
Results for "

HFD

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

1

Biochemical Assay Reagents

14

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116193

    Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    5-PAHSA increases insulin sensitivity, and has orally active anti-inflammatory and neuroprotective effects in mice HFD-induced diabetes mice. 5-PAHSA can be used for research of neurological dysfunction in diabetics .
    5-PAHSA
  • HY-N6869

    Antibiotic PPAR Bacterial Fungal Infection Metabolic Disease Inflammation/Immunology Cancer
    Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
    Dehydroabietic acid
  • HY-131448

    Others Metabolic Disease
    A3051 is a potent and orally active inhibtor of CXXC5-DVL extracted from patent WO2020079569, has an IC50 of 63.06 nM. A3334 can be used for the research of high fat diet (HFD)-induced and methionine-choline deficient diet (MCD)-induced phenotypes such as obesity, diabetes, and NASH .
    A3334
  • HY-128578

    PDHK Metabolic Disease Inflammation/Immunology
    KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice .
    KPLH1130
  • HY-N8144

    Others Cardiovascular Disease
    Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .
    Niga-ichigoside F1
  • HY-129143

    Dp3‐Sam chloride

    Others Metabolic Disease Inflammation/Immunology
    Delphinidin-3-sambubioside (Dp3‐Sam) chloride is an anthocyanin that has orally active anti-inflammatory activity. Delphinidin-3-sambubioside chloride inhibits LPS-induced inflammatory factors release. Delphinidin-3-sambubioside chloride also alleviates hepatic lipid accumulation in HFD rats. Delphinidin-3-sambubioside chloride can be isolated from Hibiscus sabdariffa L. .
    Delphinidin-3-sambubioside chloride
  • HY-N6869R

    Antibiotic PPAR Bacterial Fungal Infection Metabolic Disease Inflammation/Immunology Cancer
    Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .
    Dehydroabietic acid (Standard)
  • HY-129143R

    Others Metabolic Disease Inflammation/Immunology
    Delphinidin-3-sambubioside (chloride) (Standard) is the analytical standard of Delphinidin-3-sambubioside (chloride). This product is intended for research and analytical applications. Delphinidin-3-sambubioside (Dp3‐Sam) chloride is an anthocyanin that has orally active anti-inflammatory activity. Delphinidin-3-sambubioside chloride inhibits LPS-induced inflammatory factors release. Delphinidin-3-sambubioside chloride also alleviates hepatic lipid accumulation in HFD rats. Delphinidin-3-sambubioside chloride can be isolated from Hibiscus sabdariffa L. .
    Delphinidin-3-sambubioside chloride (Standard)
  • HY-124557

    Others Metabolic Disease Inflammation/Immunology
    Mahanimbine is an orally active alkaloid from Murraya koenigii. Mahanimbine inhibits progression of high-fat diet (HFD)-induced metabolic complications in mice .
    Mahanimbine
  • HY-161942

    PCSK9 Metabolic Disease
    PCSK9-IN-31 (Compound WX002) is an orally active PCSK9 inhibitor. PCSK9-IN-31 can lower low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) in high cholesterol fed model rats .
    PCSK9-IN-31
  • HY-113631

    PPAR Neurological Disease Metabolic Disease
    Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with Ki values of 19 nM and EC50 values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .
    Amorfrutin B
  • HY-120851

    DAGL Cannabinoid Receptor Metabolic Disease
    O-7460 is a potent and selective DAGLα inhibitor, with an IC50 of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels .
    O-7460
  • HY-N0238
    Atractylodin
    1 Publications Verification

    Atractydin

    Others Infection Inflammation/Immunology
    Atractylodin (Atractydin) is an orally active active ingredient obtained from the rhizome of Atractylodes lancea and A. chinensis. Atractylodin is a natural insecticide. Atractylodin has anti-inflammatory activity .
    Atractylodin
  • HY-138626

    Melatonin Receptor Metabolic Disease
    ACH-000143 is a potent and orally active melatonin receptor agonist, with EC50 values of 0.06 nM and 0.32 nM for MT1 and MT2, respectively .
    ACH-000143
  • HY-N7515

    2',4',6'-Trihydroxychalcone

    Bacterial AMPK Infection Metabolic Disease Inflammation/Immunology
    Pinocembrin chalcone (2',4',6'-Trihydroxychalcone) is an antibacterial compound from Helichrysum Trilineatum. Pinocembrin chalcone facilitates AMP-activated protein kinase (AMPK) activation, improves glucose tolerance, increases muscle FAO and reduces fat accumulation in the liver and skeletal muscles in high-fat diet-induced (HFD) diabetic mice. Pinocembrin chalcone is promising for research of gastric ulcers and diabetes .
    Pinocembrin chalcone
  • HY-W011012

    Adenosine Receptor Metabolic Disease
    Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
    Adenosine 5'-monophosphate disodium
  • HY-131447
    KY19382
    1 Publications Verification

    A3051

    GSK-3 Wnt β-catenin Metabolic Disease
    KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases .
    KY19382
  • HY-162703

    AMPK Metabolic Disease
    Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC50 of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .
    Lipid-lowering agent-2
  • HY-159422

    Acyltransferase Metabolic Disease
    S-309309 is an orally active and selective MGAT2 inhibitor. S-309309 can be used in metabolism-related research .
    S-309309
  • HY-12756A
    E6446 dihydrochloride
    1 Publications Verification

    Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446 dihydrochloride
  • HY-12756
    E6446
    1 Publications Verification

    Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD) Metabolic Disease Inflammation/Immunology
    E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
    E6446
  • HY-N13083

    PCSK9 Cardiovascular Disease
    PCSK9-IN-28 (Compound C11) is a PCSK9 inhibitor that can be isolated from Euphorbia esula. By binding to HNF1α, PCSK9-IN-28 inhibits PCSK9 transcription by binding to HNF1α and affecting its nuclear distribution, thereby enhancing LDLR and promoting LDL uptake. PCSK9-IN-28 exhibits significant lipid-lowering activity in the high-fat diet (HFD) mouse model and can be used in the study of hyperlipidemia .
    PCSK9-IN-28
  • HY-13662
    Lansoprazole
    2 Publications Verification

    AG-1749

    Proton Pump Bacterial Phospholipase Inflammation/Immunology Cancer
    Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    Lansoprazole
  • HY-157534

    Others Metabolic Disease
    Pancreatic lipase-IN-2 (compound 7r) is a potent inhibitor of pancreatic lipase (PL), with the IC50 value of 2.67 μM, that has anti-obesity effect .
    Pancreatic lipase-IN-2
  • HY-13662R

    AG-1749 (Standard)

    Bacterial Phospholipase Proton Pump Inflammation/Immunology Cancer
    Lansoprazole (Standard) is the analytical standard of Lansoprazole. This product is intended for research and analytical applications. Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .
    Lansoprazole (Standard)
  • HY-155517

    NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation,and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles,and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation .
    INF200
  • HY-18054
    BVT 2733
    3 Publications Verification

    11β-HSD Inflammation/Immunology
    BVT 2733 is a potent, selective, and orally active non-steroidal 11β-hydroxydehydrogenase 1 (11β-HSD1) inhibitor. BVT 2733 is potently against the mouse enzyme (IC50=96 nM) over the human enzyme (IC50=3341 nM). BVT 2733 has the potential for the study of arthritis and obesity related disease .
    BVT 2733
  • HY-120103

    Sodium Channel Metabolic Disease
    PF-06649298 is a sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor. PF-06649298 specifically interacts with NaCT with an IC50 value of 16.2 μM to inhibits the transport of citrate in human hepatocytes. PF-06649298 can be used for the research of regulating glucose metabolism and lipid metabolism .
    PF-06649298
  • HY-12608

    JNJ-39933673

    SGLT Metabolic Disease
    TA-1887 (JNJ-39933673) is a highly potent, selective and orally active SGLT2 inhibitor (IC50: 1.4 nM) with antihyperglycemic effects. TA-1887 can be used in the research of diabetes .
    TA-1887
  • HY-I0400
    N-Acetylneuraminic acid
    3 Publications Verification

    NANA; Lactaminic acid

    Tyrosinase Ras Influenza Virus Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    N-Acetylneuraminic acid
  • HY-139058

    27-Deoxyactein

    PPAR Metabolic Disease Cancer
    23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound .
    23-epi-26-Deoxyactein
  • HY-141645

    WS070117

    AMPK TGF-β Receptor NF-κB JNK AP-1 Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis .
    IMM-H007
  • HY-122591
    PTUPB
    1 Publications Verification

    COX Metabolic Disease Cancer
    PTUPB is a potent and dual sEH and COX-2 enzymes inhibitor with IC50 of 0.9 nM and 1.26 μM, respectively .
    PTUPB
  • HY-130437

    MDM-2/p53 TGF-β Receptor Caspase Infection Metabolic Disease
    p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4]. non-alcoholic fatty liver disease .
    p-nitro-Pifithrin-α
  • HY-121238

    Others Metabolic Disease
    Hyocholic Acid is a bile acid found in pig. Hyocholic Acid can also be found in urine samples from patients with cholestasis. Hyocholic Acid promotes GLP-1 secretion via activating TGR5 and inhibiting FXR in enteroendocrine cells. Hyocholic Acid is known for its exceptional resistance to type 2 diabetes .
    Hyocholic Acid
  • HY-N2953

    Fatty Acid Synthase (FASN) Metabolic Disease
    Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .
    Borapetoside E
  • HY-N0288
    Lycorine
    Maximum Cited Publications
    13 Publications Verification

    Fatty Acid Synthase (FASN) Virus Protease Bacterial Apoptosis Inflammation/Immunology Cancer
    Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a Kd value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription . Lycorine is also a melanoma vasculogenic inhibitor . Lycorine can be used for the study of prostate cancer and metabolic diseases .
    Lycorine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: